Evidence map›Paper›PMID 41462253›Full record

ArticleCell communication and signaling : CCS2025

Uromodulin alleviates fibrosis in acute kidney injury to chronic kidney disease transition by reducing EGFR.

Zheyu Xing, Kunjing Gong, Na Wang, Lufeng Bai, Nan Hu, Di Song, Yuqing Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zheyu XingRenal Division, Peking University First Hospital, No.8. Xishiku Street, Beijing, China.
Kunjing GongRenal Division, Peking University First Hospital, No.8. Xishiku Street, Beijing, China.
Na WangRenal Division, Peking University First Hospital, No.8. Xishiku Street, Beijing, China.
Lufeng BaiRenal Division, Peking University First Hospital, No.8. Xishiku Street, Beijing, China.
Nan HuRenal Division, Peking University First Hospital, No.8. Xishiku Street, Beijing, China.
Di SongRenal Division, Peking University First Hospital, No.8. Xishiku Street, Beijing, China.
Yuqing ChenRenal Division, Peking University First Hospital, No.8. Xishiku Street, Beijing, China. cyq@bjmu.edu.cn.

Funding

CAMS Innovation Fund for Medical Sciences 2019-I2M-5-046National High Level Hospital Clinical Research Funding 2022CX13National Natural Science Foundation of China 82070749
6 · The paper itself

Abstract

backgroundUromodulin has been speculated as a protective factor for acute kidney injury (AKI) and chronic kidney disease (CKD), possibly based on the uromodulin-mediated cross-talk between thick ascending limbs and proximal tubules. Here, we explored the roles of uromodulin in the AKI-CKD transition.

methodsWild-type SD rats and UMOD

resultsUMOD

conclusionsCollectively, we discovered uromodulin may alleviate the progression of AKI-CKD transition via the EGFR suppression.

Indexed as

Acute Kidney InjuryErbB ReceptorsRenal Insufficiency, ChronicUromodulinAnimalsCell LineCisplatinDisease Models, AnimalFibrosisHumansMaleMolecular Docking SimulationRatsRats, Sprague-DawleySignal TransductionCisplatinErbB ReceptorsUromodulinAKI-CKD transitionEGFRRenal fibrosisUromodulin

Identifiers

PMID41462253
PMCPMC12751814

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.